Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation boost after chemo shows promise for tough lung cancers

NCT ID NCT00945451

Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a precise, high-dose radiation treatment called CyberKnife after standard chemo and radiation could help people with stage III non-small cell lung cancer. It included 35 patients who had 1 to 3 small tumors left after initial treatment. The goal was to find the safest dose and see how well it shrank tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CyberKnife radiosurgery (a precise type of radiation)
What this could lead to
If it works, this could offer a way to boost tumor control for people with stage III lung cancer who cannot have surgery.
What could go wrong
This was a small, early-phase study (35 people) looking at side effects and best dose, not a large test of effectiveness. The added radiation may cause more lung or esophageal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Apr 2009

Finished

Nov 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * Locally advanced disease * No metastatic disease * Unable to undergo surgery after concurrent chemoradiotherapy * Must have 1-3 tumor target masses \< 5 cm in greatest diameter and separated by ≥ 2 cm after concurrent chemoradiotherapy PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Platelet count \> 100,000/mm³ * Hemoglobin \> 9 g/dL * Neutrophil \> 1.0 x 10\^9/L * FEV\_1 \> 30% of vital capacity * Vital capacity \> 25% of predicted value * DLCO \> 25% of predicted value * LVEF ≥ 35% * PT \> 80 * aPTT \> 35 sec * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * Not under guardianship * No dyspnea related to NYHA class III-IV heart failure * No indirect signs of pulmonary arterial hypertension (pulmonary arterial systolic BP \> 45 mm Hg) * No pulmonary acceleration time \< 100 ms * No contraindication to fiducial insertion * No geographical, social, or psychological conditions that would interfere with medical follow-up PRIOR CONCURRENT THERAPY: * Docetaxel and platinum-based drugs with concurrent irradiation allowed * No prior surgery or surgery after the first phase of treatment with concurrent chemoradiotherapy * No prior irradiation to lung * No concurrent participation in another study trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.